• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Intercure Ltd.

    11/25/24 4:30:30 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INCR alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

     

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the month of November 2024

     

    Commission File Number: 001-40614

     

    INTERCURE LTD.

    (Translation of registrant’s name into English)

     

    85 Medinat ha-Yehudim Street

    Herzliya, 4676670, Israel

    Tel: +972 77 460 5012

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    On November 25, 2024, Intercure Ltd. (the “Company”) announced that it will hold its Annual General Meeting of Shareholders (the “Meeting”) on December 30, 2024 at 4:00 p.m. (Israel time) at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross., 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the Meeting, the Company furnishes the following documents:

     

      1. A copy of the Notice and Proxy Statement with respect to the Meeting describing the proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting, attached hereto as Exhibit 99.1; and

     

      2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the Meeting without attending in person, attached hereto as Exhibit 99.2.

     

    Exhibit Index

     

    Exhibit No.   Description
         
    99.1   Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders
         
    99.2   Proxy Card for holders of ordinary shares with respect to the Company’s Annual General Meeting of Shareholders

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      INTERCURE LTD.
       
    Date: November 25, 2024 /s/ Amos Cohen
     

    Amos Cohen

      Chief Financial Officer

     

     

     

    Get the next $INCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INCR

    DatePrice TargetRatingAnalyst
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    More analyst ratings

    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

      2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. InterCure received NIS 62 million until December 31, 2024 (to date, NIS 82 million) as partial advanced payments from the Israeli authorities and expects to receive additional substantial payments.Revenues in 2024 reached NIS 239 million, alongside an Adjusted EBITDA[1] of NIS 24 million (approximately 10% of revenues).InterCure announced expansion of its strategic partnership with Cookies™ to Germany and expec

      5/1/25 4:00:00 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

      NEW YORK and HERZLIYA, Israel, Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company (the "Board"), effective February 13, 2025. He will be succeeded by Mr. Alexander Rabinovich, who has successfully led the Company as CEO for the past five years, executing hundreds of percentages of profitable growth, building strategic international partnerships, and establishing InterCure's position as a leader in pharmaceutical cannabis. Mr. Barak, who is marking his 83rd birthday today, has decided to pursue personal endeavors after six

      2/12/25 6:35:00 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

      The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war.The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. Funding also includes a loan from a major Israeli bank.Completing the post-war damage recovery processes will enable the company to return to profitable growth without further delay, including exercising the cookies agreement and expanding international operations in Germany, the UK, and Australia.The Company anticipates receiving additional substantial p

      12/20/24 8:32:00 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Financials

    Live finance-specific insights

    See more
    • InterCure Reschedules 2022 Full Year Results Conference Call

      NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

      4/3/23 3:27:01 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

      Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

      3/31/23 8:00:49 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Reports Record Breaking Second Quarter Financial Results

      Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

      8/15/22 9:15:00 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intercure Ltd.

      SC 13G - Intercure Ltd. (0001857030) (Subject)

      5/16/22 1:02:53 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    SEC Filings

    See more
    • SEC Form 6-K filed by Intercure Ltd.

      6-K - Intercure Ltd. (0001857030) (Filer)

      5/1/25 4:10:06 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Intercure Ltd.

      20-F - Intercure Ltd. (0001857030) (Filer)

      4/30/25 9:42:57 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 20-F filed by Intercure Ltd.

      NT 20-F - Intercure Ltd. (0001857030) (Filer)

      4/30/25 8:14:01 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InterCure upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

      5/18/22 7:21:05 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care